Thursday, September 29, 2022
Irene Ganan-Gomez - The University of Texas MD Anderson Cancer Center
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy